Press Releases

Glox Therapeutics Awarded Share of £3M Collaborative Discovery Programme Funding from Cystic Fibrosis Antimicrobial Resistance Syndicate

• £500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis • Programme delivered by CF AMR Syndicate offers cross-sector collaboration and support to address urgent unmet need

Pharmapack Europe the ‘Heart of Pharma’ Start-ups in Paris

At Pharmapack Europe 2025, six exceptional start-ups have been honoured with the prestigious ‘Heart of Pharma’ awards, recognising their groundbreaking contributions to drug delivery, packaging, and patient care. Selected from a competitive field of 26 innovators, these companies are transforming healthcare with technologies that promise to revolutionize industry standards. The winners include innovations such as sustainable biofuel-powered electronics, patient-friendly nasal sprays, next-generation intradermal drug delivery devices, and breakthrough vial-filling systems. Representing global excellence, recipients hail from the U.S., UK, Ireland, France, and the DACH region. With over 6,000 attendees and 370 exhibitors, Pharmapack remains the must-attend event for pharma innovation. Don’t miss the chance to cover these transformative start-ups and their award-winning technologies.

UK Biocentre Selects the Azenta Life Sciences BioArc Ultra Automated Storage System to Advance Research Excellence

UK Biocentre has selected the BioArc Ultra™ automated storage system to expand their capacity for large-scale biomedical research by an additional 16million samples, supporting vital projects like the UK’s largest health research program, Our Future Health.

Pharmapack Europe Awards 2025 Winners

Pharmapack Europe 2025 proudly announces the winners of its newly reformatted Pharmapack Awards, recognising excellence across six transformative categories in pharmaceutical packaging and drug delivery. This year’s honourees include innovative advancements in sustainable materials, patient-centered design, and next-generation devices—all poised to redefine healthcare delivery. Notable winners include SHL Medical’s Elexy™ reusable electromechanical autoinjector, Huhtamaki’s Omnilock™ Ultra PAPER for eco-friendly packaging, and Mitsubishi Gas Chemical’s OXYCAPT multilayer vial for gene therapy. The prestigious Woman of the Year Award celebrates Asmita Khanolkar of SMC Ltd. for her decades-long contributions to drug-device innovation.

The MAP Group Unites Three Companies Under One New Brand Name, Kintiga

The MAP Group unites three companies under one new brand name, Kintiga

MaxisIT Launches Site Copilot: A Conversational AI Solution to Transform Clinical Trial Site Operations

MaxisIT introduces Site Copilot, an AI-driven conversational agent built on DTect AI, designed to streamline clinical trial site operations. It enhances regulatory compliance, quality management, and patient engagement by integrating seamlessly into existing workflows.

PhaseV and Alimentiv Partner on ML-Based Solution to Tackle Challenges in GI Clinical Trials

PhaseV's Adaptive Clinical Trials Platform Will Support the Gastrointestinal CRO in Addressing a Wide Range of GI-Related Conditions

Upperton Pharma completes build of new £7m sterile manufacturing facility

Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of its new sterile manufacturing facility in Nottingham, UK.

Cold Chain Technologies and Tower Cold Chain Celebrate Landmark Sustainability Achievements

Cold Chain Technologies (CCT) and Tower Cold Chain, a subsidiary of CCT, have reached important milestones in their ongoing commitment to sustainability.

Veteran Clinical Research Executive Steve Clemons Joins ObjectiveHealth as CEO

ObjectiveHealth, a Nashville-based integrated research and technology platform company, announced today that veteran clinical research executive Steve Clemons has joined the company as CEO.

Peak Heart & Vascular Launches Exclusive Research Partnership with Axsendo Clinical Research

About Peak Heart & Vascular Peak Heart & Vascular is a leading cardiovascular practice serving the Phoenix metropolitan area and Northern Arizona, dedicated to providing comprehensive heart and vascular care. Founded by a team of highly seasoned, board-certified cardiologists, electrophysiologists, and vascular surgeons, the practice is highly regarded within the community and has been awarded for excellence in patient care, innovation, and research. In addition to its clinical offices, Peak Heart & Vascular operates state-of-the-art outpatient surgery centers, offering patients access to minimally invasive procedures in a convenient and cost-effective setting. These centers have earned The Joint Commission’s Gold Seal of Approval ® Accreditation, ensuring the highest standards of safety and care. Learn more at peakheart.com. About Axsendo Clinical Research Axsendo Clinical Research is a leading clinical research organization dedicated to advancing medical science through innovative clinical trials. With a focus on bringing research opportunities closer to diverse communities, Axsendo partners with healthcare providers across multiple specialties to improve patient access to cutting-edge treatments. For more information, visit www.axsendoclinicalresearch.com. For more information: Peak Heart & Vascular Shawn Smith media@peakheart.com 602.698.7325 Axsendo Clinical Research info@axsendoclinical.com 844.290.2273

Caidya Announces $165 Million Strategic Growth Investment From Rubicon Founders

Caidya today announced the closing of a strategic growth investment of $165 million from funds managed by Rubicon Founders.

Chromatin Bioscience’s synthetic promoter supports EsoBiotec’s ESO-T01 CAR-T therapy as it enters the clinic

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical stage and utilises a synthetic promoter designed using Chromatin Bio’s proprietary promoter design platform, chromatinLENS, exclusively for EsoBiotec as part of its innovative approach to immunotherapy.

Coronado Research announce appointment of Jo Marshall as EVP Data Services and Advanced Analytics

Coronado Research is pleased to announce the appointment of Jo Marshall as EVP of Data Services and Advanced Analytics.

Biofidelity and CellCarta partner to deploy Aspyre® Lung in global clinical trials

Biofidelity and CellCarta have announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials.

Kindeva Drug Delivery and Emervax Partner To Bring Game Changing Vaccine Administration to Patients

STEMart Announces Balloon Catheter Testing Services to Ensure Medical Device Safety and Regulatory Compliance

STEMart introduces Balloon Catheter Testing Services for the development of safe and effective medical devices.

PrecisionLife Appoints Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare

PrecisionLife announces the appointment of Bill Keating as Chief Commercial Officer, Diagnostics and Healthcare.

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for National Cancer Institute’s Vanguard Study

ClearNote Health announced that its Avantect Multi-Cancer Detection Test was selected for the National Cancer Institute’s new Vanguard Study.

Quris-AI's Bio-AI Platform Integrated by Merck KGaA, Darmstadt, Germany for Preclinical Small Molecule Drug Safety Evaluation

Following an expanded collaboration between AI innovator Quris-AI and Merck KGaA and a two-year validation study to test clinical safety prediction by identifying drug candidate liver toxicity risks, it was announced this morning that Merck KGaA has adopted the startup's platform to test small molecule drug candidates prior to initiating clinical trials. Quris-AI’s platform integrates advanced AI, machine learning, generative models, patient-on-chip technology, and proprietary data to predict potential drug-induced toxicities better.